Indian Pharma Market Grew Marginally Lower At 7.5% In February 2025
Indian Pharmaceuticals Market has delivered marginally lower revenue at 7.5% year on year in February 2025, compared to 8.7% year on year in January 2025. Overall, growth in February was driven by growth in price (5.2% YoY) and new launches (2.4% YoY), while volume growth continued to remain muted at negative 0.2% YoY.
Year-to-date in FY25, IPM reported growth at an average of 7.3% year on year, led by price growth at 5.5%, new launches growth at 2.7% and volume growth at negative 0.8%.
Among the top 10 therapies, cardiac, gastro, neuro/CNS, and derma outperformed IPM growth, while weak growth was seen in anti-infectives, respiratory, and gynaec therapies in February.
Ind-Ra expects IPM growth to be at 7.5-8.0% year on year for FY25 (FY26: 8-9% year-on-year) against 6.5% year-on-year in FY24 and 9.9% YoY growth in FY23, Krishnanath Munde, associate director at India Ratings and Research, told NDTV Profit.
Key Highlights
Volume growth decreased 0.2%. It saw 0.2% growth in February 2024.
Price growth of 5.2% in February, as compared to 5.8% over the same period last year.
New launches increased 2.4%, as against 3% in February 2024.
MAT Performance
The moving annual total—or the 12-month rolling sales of overall pharma products—increased 8.1% in February.
Outperformers
Zydus Lifesciences Ltd. led the market with the highest growth at 12.7%, followed closely by Ajanta Pharma Ltd. with 11.8% and Torrent Pharma Ltd. with 11.6%.
FDC and JB Chemicals also demonstrated strong performance, achieving growth rates of 11.3% and 11.0%, respectively. Sun Pharmaceutical Industries Ltd., Pfizer India, Dr. Reddy's, Ipca Labs, and Lupin Ltd. all outperformed the overall market growth, indicating robust market traction and successful strategic execution.
In-Line Performers
Mankind Pharma and Glenmark Pharmaceuticals both reported a 7.8% growth, aligning closely with the overall market performance.
Abbott India achieved a 7.7% growth, while Alkem Labs and Emcure Pharmaceuticals saw growth rates of 7.5% and 7.2%, respectively, indicating stable operational performance consistent with the market average.
Underperformers
Cipla and Eris Lifesciences experienced slower growth at 5.3% and 5.4%, respectively.
Alembic Pharma and Indoco Remedies both reported a 3.7% growth, while GlaxoSmithKline Pharma saw a 2.7% increase.
Sanofi India reported a negative growth of 0.5%, indicating potential challenges or market-specific factors adversely affecting their performance.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
